Company profile
TELA Bio, Inc.
NASDAQ: TELA · Healthcare · Medical - Devices
#374 of 1,418 Healthcare companies by revenue62nd-percentile growth
EA Score
47DFH 37DQ 48GM 70SS 53
v0.1 · 65/100 weight · provisional
↑ growth stability, workforce scale · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$80.8M
Rev growth YoY (TTM)
+13.5%
Net income (FY)
-$38.8M
Employees
218
as of 2026-08-20
Market cap
$28.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$80.3M$80.3M2025
Net income-$38.8M-$38.8M2025
Operating income-$33.8M-$33.8M2025
Total assets$81.4M$81.4M2025
Liabilities$75.1M$75.1M2025
Equity$6.3M$6.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is TELA Bio, Inc.’s revenue?
TELA Bio, Inc. booked $80.3M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a -48.4% net margin.
Peers · Healthcare
Arcturus Therapeutics Holdings Inc.49DMeiraGTx Holdings plc48DDecibel Cannabis Company Inc.62CEton Pharmaceuticals, Inc.60CVitalhub Corp.77B+Sight Sciences, Inc.53DNeighbors
Chester →Key facts
CEOHeather Getz
SectorHealthcare
IndustryMedical - Devices
HeadquartersMalvern, PA
ExchangeNASDAQ: TELA
Employees218
IPO date2019-11-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.